Drug intelligence / Profile preview

YYD601

Development stage: Phase 3
Lead developer: Yooyoung Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

YYD601 is a pharmaceutical drug developed by Yooyoung Pharmaceutical Co., Ltd. It is a novel oral formulation combining immediate-release (IR) and sustained-release (SR) esomeprazole, with dosages such as 10mg IR and 10mg SR. This drug is being investigated for the treatment of various gastroesophageal reflux conditions, including Gastroesophageal Reflux Disease (GERD), Non-Erosive Reflux Disease (NERD), and Esophageal Reflux Disease (ERD). Esomeprazole, its active ingredient, is a proton pump inhibitor.

Other names: Esomeprazole magnesium dehydrate

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on YYD601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YYD601.

Explore the full profile